Clinical trial

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

NCT00695292

Study summary

ClinicalTrials.gov

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record irinotecan Normalized identity: irinotecan View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record sunitinib Normalized identity: sunitinib View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-06-01

PhasePHASE2

Conditions

Small Cell Lung Cancerverified · MONDO: small cell lung carcinoma

Interventions

irinotecanDRUG · verified · RxNorm: irinotecan

CarboplatinDRUG · verified · RxNorm: carboplatin

sunitinibDRUG · verified · RxNorm: sunitinib

Sponsors & collaborators

SCRI Development Innovations, LLClead sponsor

Pfizercollaborator

Mapped research locations

NashvilleTennessee, United States1 CincinnatiOhio, United States1 OrlandoFlorida, United States1 BethesdaMaryland, United States1 SpartanburgSouth Carolina, United States1 Baton RougeLouisiana, United States1 Fort MyersFlorida, United States1 ChattanoogaTennessee, United States1 ChesterfieldMissouri, United States1 GainesvilleGeorgia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00695292 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.